Corinne O'Brien Email and Phone Number

Led development and execution of strategic growth initiatives for global business unit (Pfizer Essential Health: primarily mature portfolios, $21 B Revenue). • Developed strategic investment plan to reshape growth trajectory of the business unit and optimize capital allocation. Drove increase in projected growth rate and outlined roadmap for sequence of business development initiatives. • Managed team of 6 experienced professionals responsible for identifying high-impact business development initiatives and partnering across functions to manage all aspects of deal evaluation, diligence and execution. •Led strategic initiatives for the Anti-Infectives business segment, including acquisition of AstraZeneca small-molecule portfolio and license of Basilea product (combined estimated purchase price ~ $3 B*). Supported integration and ongoing business model evolution as core member of Anti-Infectives Leadership Team. (*Amounts communicated in press releases)• Restructured strategy, search and evaluation functions to effect dynamic prioritization of diverse initiatives and improve profitability. Balanced standardization with flexibility to implement nimble structure, streamlined processes and established clear collaboration guidelines. • Established center of excellence for opportunity evaluation. Automated routine data aggregation – eliminating over 60 analyst hours per quarter, reducing error risk and ensuring use of consistent information base. Bolstered capabilities in valuation, data visualization, business case construction.• Advised regional/functional leads on range of strategic and operational issues: brainstorming, facilitating decisions and proactively driving non-routine initiatives.

Built and led the finance team responsible for U.S gross-to-net financial planning and reporting. Covered rebates, returns and chargebacks for >200 products (~15% of sales) and managed extensive coordination across departments. • Restructured the function to manage an evolving portfolio and an increasingly dynamic U.S. regulatory environment. Effectively implemented all provisions of the 2010 Affordable Care Act and other relevant regulation and managed timely integration of acquired portfolios (e.g. Wyeth integration 2010).• Led the design and construction of fit-for-purpose system to synthesize vast amounts of data and facilitate analytics. Significantly advanced ability to act on evidence-based insight• Frequent presenter and panel member at Finance and Accounting Conferences covering gross-to-net function and revenue recognition (e.g. CBI annual Gross-to-Net Conference).

> Led sales forecasting, competitive intelligence and decision analytics for in-line and pipeline products (CNS portfolio). Influenced development and execution of brand strategy, managed coordination with copromote partners and supported business development activity.> Faciliated training and development activities to advance capabilities across global organization (market research, financial statement analysis, analytical modeling)